

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM700354

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
OXFORD FINANCE LLC		12/29/2021	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	MOLECULIGHT INC.		
<b>Street Address:</b>	101 College street		
<b>Internal Address:</b>	Suite 200		
<b>City:</b>	Toronto		
<b>State/Country:</b>	CANADA		
<b>Postal Code:</b>	M5G 1L7		
<b>Entity Type:</b>	Corporation: CANADA		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86401007	MOLECULIGHT	
<b>Serial Number:</b>	86719252	LOOK TO HEAL	
<b>Serial Number:</b>	87511866	I:X	
<b>Serial Number:</b>	87563052	MOLECULIGHT DARKDRAPE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4168657380		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	14168657697		
<b>Email:</b>	jkkim@torys.com		
<b>Correspondent Name:</b>	TORYS LLP		
<b>Address Line 1:</b>	79 Wellington St. W., 30th Floor, Box 27		
<b>Address Line 4:</b>	Toronto, CANADA M5K 1N2		
<b>NAME OF SUBMITTER:</b>	Julie Kim		
<b>SIGNATURE:</b>	/Julie Kim/		
<b>DATE SIGNED:</b>	01/06/2022		
<b>Total Attachments: 7</b>			
source=62021445_v_3_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021			

OP \$115.00 86401007

(Executed)#page1.tif  
source=62021445\_v 3\_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021  
(Executed)#page2.tif  
source=62021445\_v 3\_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021  
(Executed)#page3.tif  
source=62021445\_v 3\_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021  
(Executed)#page4.tif  
source=62021445\_v 3\_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021  
(Executed)#page5.tif  
source=62021445\_v 3\_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021  
(Executed)#page6.tif  
source=62021445\_v 3\_Oxford (Moleculight)- Termination and Release of IP Security Agreement- December-2021  
(Executed)#page7.tif

**TERMINATION AND RELEASE OF  
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Termination and Release of Intellectual Property Security Agreement (this “**Termination**”), dated as of December 29, 2021, is executed by **OXFORD FINANCE LLC**, a Delaware limited liability company, as collateral agent (“**Collateral Agent**”) for the Lenders described in the Loan and Security Agreement, dated as August 13, 2019 (the “**Loan and Security Agreement**”), in favor of **MOLECULIGHT INC.**, an Ontario corporation, **MOLECULIGHT CORP.**, a Delaware corporation, **MOLECULIGHT INTERNATIONAL INC.**, an Ontario corporation, and **MOLECULIGHT ONCOLOGY INC.**, an Ontario corporation (individually and collectively, jointly and severally, “**Debtor**”). All capitalized terms used in this Termination and not otherwise defined herein, shall have the respective meanings given to such terms in the Loan and Security Agreement.

**RECITALS**

A. Pursuant to the terms of the Loan and Security Agreement, Debtor granted to Collateral Agent, for the benefit of the Lenders, a security interest in the Intellectual Property of the Debtor.

B. Debtor and Collateral Agent entered into that certain Intellectual Property Security Agreement, dated as of August 13, 2019 (the “**IP Security Agreement**”), by and between Debtor and Collateral Agent, which was recorded with the Patent Division of the United States Patent and Trademark Office and the Canadian Intellectual Property Office on or about August 14, 2019, to evidence the security interests granted under the Loan and Security Agreement and the IP Security Agreement.

C. The IP Security Agreement was recorded with the Trademark Division of the United States Patent and Trademark Office on August 14, 2019, to evidence the security interest granted under the Loan and Security Agreement.

D. The IP Security Agreement was recorded with the Patent Division of the United States Patent and Trademark Office on August 14, 2019, to evidence the security interest granted under the Loan and Security Agreement.

E. The IP Security Agreement was recorded with the Canadian Intellectual Property Office in respect of the trademarks set forth on Exhibit C on November 26, 2019, to evidence the security interest granted under the Loan and Security Agreement.

F. The IP Security Agreement was recorded with the Canadian Intellectual Property Office in respect of the industrial designs set forth on Exhibit D on August 27, 2019, to evidence the security interest granted under the Loan and Security Agreement.

G. In connection with Debtor’s repayment of all obligations outstanding under the Loan Agreement, the Collateral Agent’s and the Lenders’ security interests and liens on the Collateral have terminated and been released, and

Collateral Agent has executed this Termination in order to evidence the termination and release of its and the Lenders’ security interest in the Intellectual Property of the Debtor.

**AGREEMENT**

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Collateral Agent hereby agrees as follows:

(a) Collateral Agent expressly terminates, releases and discharges all of Collateral Agent's right, title and interest in, to and under the Intellectual Property of the Debtor (including but not limited to each of the Copyrights, Patents, Trademarks and Industrial Designs listed on Exhibits A, B, C and D hereto).

(b) Collateral Agent represents and warrants that it has the full power and authority to execute this Termination.

(c) Collateral Agent authorizes and requests the patent division and the trademark division of the United States Patent and Trademark Office to record this Termination.

(d) Collateral Agent authorizes and requests the Canadian Intellectual Property Office to record this Termination.

*[Signature Page Follows]*

IN WITNESS WHEREOF, Collateral Agent has executed and delivered this Termination as of the day and year first above written.

**OXFORD FINANCE LLC**

By: \_\_\_\_\_

Name: Colette H. Featherly

Title: Senior Vice President

*[Signature Page to Termination and Release of IP Security Agreement]*

**TRADEMARK**  
**REEL: 007552 FRAME: 0276**

Exhibit A

Copyrights

None.

Exhibit B

Patents

<u>Property Type</u>	<u>Patent/App. No.</u>
Application Number	62625611
Application Number	62669009
Application Number	62793842
Application Number	62863771
Application Number	29497404
Application Number	29497405
Application Number	29505784
Application Number	29638857
Application Number	29638861
Application Number	29647110
Application Number	29647052
Application Number	29676893
Application Number	29676901

Exhibit C

Trademarks

U.S.A.:

<u>Word Mark</u>	<u>Serial/Registration No.</u>	<u>File Date</u>
MOLECULIGHT	86401007	December 6, 2016
LOOK TO HEAL	86719252	December 6, 2016
1:X	87511866	June 18, 2019
MOLECULIGHT DARKDRAPE	87563052	March 6, 2018

Canada:

	<b>Mark</b>	<b>Application #</b>	<b>Registration #</b>
1	<b>MOLECULIGHT</b>	1689375	933046
2	<b>LOOK TO HEAL</b>	1723451	941457
3	<b>MolecuLight DarkDrape</b>	1747707	977765
4	<b>i:X</b>	1839879	1013603



Exhibit D

Industrial Designs

	<b>Title</b>	<b>#</b>
1	<i>Handheld portable imaging device</i>	169795
2	<i>Handheld portable imaging device</i>	174402
3	<i>Handheld portable imaging device</i>	174403
4	<i>Handheld portable imaging device</i>	174404
5	<i>Handheld portable imaging device</i>	174405
6	<i>Darkening drape</i>	184575
7	<i>Adapter for supporting a darkening drape</i>	188609
8	<i>Handheld imaging device</i>	188611